IOVANCE BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 0.36% for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-06.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2021-05-06
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-03-31 was 0.36%, a 80.33% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-03-31 was 1.83%, a 29.34% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2019-03-31 was 2.59%.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-09-30 was 1.57%.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2015 was 1.56%.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2013 was 2.67%, a 50.00% increase from fiscal 2012.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2012 was 1.78%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2021-03-31 | 0.36% 10-Q · filed 2021-05-06 | |||
| 2020-03-31 | 1.83% 10-Q · filed 2021-05-06 | |||
| 2019-06-30 | 2.59% 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | 2.59% 10-Q · filed 2020-05-05 | |||
| 2015-12-31 | 1.56% 10-K · filed 2018-03-12 | |||
| 2015-09-30 | 1.57% 10-Q · filed 2016-11-04 | 1.57% 10-Q · filed 2016-11-04 | ||
| 2014-06-30 | 1.88% 10-Q · filed 2014-08-08 | |||
| 2014-03-31 | 1.75% 10-Q · filed 2014-05-14 | |||
| 2013-12-31 | 2.67% 10-K · filed 2014-03-28 | |||
| 2012-12-31 | 1.78% 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |